Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24129611 | 0.72 | MEN1 (0.32) | MEN1KMT2AUSP2SIGMAR1 | |
| SCHEMBL5549331 | 0.68 | KDM1A (0.50) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL18723632 | 0.67 | USP2 (0.36) | USP2SIGMAR1 | |
| SCHEMBL15558494 | 0.64 | USP2 (0.32) | MEN1KMT2AUSP2SIGMAR1 | |
| SCHEMBL24273015 | 0.64 | MEN1 (0.35) | MEN1KMT2AUSP2SIGMAR1 | |
| SCHEMBL9234892 | 0.61 | AKR1B1 (0.57) | MEN1KMT2A | |
| SCHEMBL8622849 | 0.60 | — | — | |
| SCHEMBL7782439 | 0.59 | KDM1A (0.44) | SIGMAR1 | |
| SCHEMBL12409769 | 0.58 | — | — | |
| SCHEMBL8023504 | 0.57 | SIGMAR1 (0.39) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 551/4885KMT2A 2868/4885SLC6A3 3833/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | MEN1 551/4885KMT2A 2868/4885SLC6A3 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.